Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorecta
A phase 3 trial of Petosemtamab, Cetuximab, FOLFIRI in colorectal cancer, run by Genmab, now recruiting.
Overview
Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer (LiGeR-CRC1) is a phase 3 interventional study registered as NCT07702032 by Genmab, with 960 participants planned, started 2026-08-11 and due to reach its primary completion in 2029-07. Interventions recorded: Petosemtamab, Cetuximab, FOLFIRI, mFOLFOX6. Conditions listed: Left-sided Colorectal Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
Shares Petosemtamab, FOLFIRI (5-FU, leucovorin, irinotecan), FOLFOX (5-FU, leucovorin, oxaliplatin), Genmab.
- TrialStudy of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metast
Shares Petosemtamab, Genmab, Cetuximab, Colorectal cancer.
- TrialA Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma P
Shares Petosemtamab, Genmab.
- TrialHSK42360-Na Tablets Combined With Cetuximab With or Without Chemotherapy in BRAF V600-Mutant Metastatic Colorectal Cancer
Shares FOLFIRI (5-FU, leucovorin, irinotecan), Cetuximab, Colorectal cancer.
- PairingAnti-EGFR antibody + chemotherapy in left-sided RAS/BRAF wild-type mCRC
Shares FOLFIRI (5-FU, leucovorin, irinotecan), FOLFOX (5-FU, leucovorin, oxaliplatin), Cetuximab, Colorectal cancer.
- TrialStudy of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab fo
Shares FOLFIRI (5-FU, leucovorin, irinotecan), FOLFOX (5-FU, leucovorin, oxaliplatin), Colorectal cancer.
- TrialA Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Parti
Shares FOLFIRI (5-FU, leucovorin, irinotecan), FOLFOX (5-FU, leucovorin, oxaliplatin), Colorectal cancer.
- TrialA Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Cetuximab, Colorectal cancer.